INHIBODY©: an ultra-specific labeling tool for measuring active glucocerebrosidase in Gaucher patients and determining the biodistribution of therapeutic enzyme

Prof. Hans Aerts of the AMC and Prof. Hermen Overkleeft from Leiden University have generated a
GBA inhibitor that binds to active glucocerebrosidase only and thus for the first time provides a means to
accurately determine the level of active enzyme. This allows more exact dosing of the very costly therapeutic enzyme, which could result in major savings in the treatment of Gaucher patients. In addition, labeling of trace amounts of IR-labeled therapeutic enzyme could be used to determine the biodistribution of GBA and allow rational ERT.


Click here for more information on this collaboration opportunity